Absence of p53 Overexpression and Favorable Response to Cisplatin‐based Neoadjuvant Chemotherapy in Urothelial Carcinomas

It has been controversial whether cancer cells harboring loss or inactivation of the tumor suppressor p53 are resistant or sensitive to DNA‐damaging agents including cisplatin and doxorubicin. Overexpression of mdm2 oncoprotein, a negative regulator of p53, is assumed to be an alternative to p53 dys...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakehi, Yoshiyuki, Özdemir, Enver, Habuchi, Tomonori, Yamabe, Hirohiko, Hashimura, Takayuki, Katsura, Yoshitaka, Yoshida, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1998
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921759/
https://www.ncbi.nlm.nih.gov/pubmed/9548450
http://dx.doi.org/10.1111/j.1349-7006.1998.tb00551.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921759/
https://www.ncbi.nlm.nih.gov/pubmed/9548450
http://dx.doi.org/10.1111/j.1349-7006.1998.tb00551.x

Ejemplares similares